Equity Profile

CRNX

Crinetics Pharmaceuticals, Inc.

Health CarePharmaceuticals$3.7B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and can influence investor sentiment.

N/A

Revenue

Revenue growth is essential to assess the company's market performance and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and disorders. With a market cap of $4 billion, it operates in the pharmaceuticals industry, which is crucial for addressing unmet medical needs and improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of -$1.23, slightly missing estimates. The stock reacted positively, increasing by 4.27% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent stock performance despite EPS misses.

Bull Case

If Crinetics can show improved revenue or reduced losses, it could bolster investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, continued losses or lack of revenue growth could raise concerns about the company's viability and lead to a stock decline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

The EPS figure will be crucial in determining whether the company is making progress toward profitability or if losses are continuing.

Is there any guidance on revenue growth or product pipeline updates?

Insights into revenue and the product pipeline will help investors gauge the company's future prospects and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Crinetics to reduce its losses significantly this quarter, given recent product developments.

Supporting Evidence

Options are pricing in a larger move than the stock has historically shown, indicating potential for a surprise.

The recent stock performance suggests investor sentiment may be more optimistic than the underlying fundamentals.

The company's ongoing research could yield positive news that isn't reflected in current estimates.

Key Risk

If the EPS loss is significantly lower than expected, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in assessing whether Crinetics can turn around its financial performance amidst ongoing challenges.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would confirm a positive trend in financial performance.

Bear Confirmed If

An EPS loss greater than -$1.30 would reinforce concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±17.74%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around +1.42%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with history suggesting an average move of -1.90% following such outcomes.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming trials.
2Details on cost management strategies and their impact on EPS.
3Insights into market demand for current and future products.
4Management's outlook on revenue growth for the upcoming quarters.
5Responses to questions about competitive positioning in the pharmaceutical market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and can influence investor sentiment.

N/A

Revenue

Revenue growth is essential to assess the company's market performance and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of -$1.23, slightly missing estimates. The stock reacted positively, increasing by 4.27% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent stock performance despite EPS misses.

Bull Case

If Crinetics can show improved revenue or reduced losses, it could bolster investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, continued losses or lack of revenue growth could raise concerns about the company's viability and lead to a stock decline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

The EPS figure will be crucial in determining whether the company is making progress toward profitability or if losses are continuing.

Is there any guidance on revenue growth or product pipeline updates?

Insights into revenue and the product pipeline will help investors gauge the company's future prospects and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Crinetics to reduce its losses significantly this quarter, given recent product developments.

Supporting Evidence

Options are pricing in a larger move than the stock has historically shown, indicating potential for a surprise.

The recent stock performance suggests investor sentiment may be more optimistic than the underlying fundamentals.

The company's ongoing research could yield positive news that isn't reflected in current estimates.

Key Risk

If the EPS loss is significantly lower than expected, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in assessing whether Crinetics can turn around its financial performance amidst ongoing challenges.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would confirm a positive trend in financial performance.

Bear Confirmed If

An EPS loss greater than -$1.30 would reinforce concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±17.74%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around +1.42%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with history suggesting an average move of -1.90% following such outcomes.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming trials.
2Details on cost management strategies and their impact on EPS.
3Insights into market demand for current and future products.
4Management's outlook on revenue growth for the upcoming quarters.
5Responses to questions about competitive positioning in the pharmaceutical market.